Top

International Journal of Clinical Oncology

Published in:

01-02-2018 | Original Article

Presurgical axitinib therapy increases fibrotic reactions within tumor thrombus in renal cell carcinoma with thrombus extending to the inferior vena cava

Authors: Yoshimi Tanaka, Shingo Hatakeyama, Shogo Hosogoe, Toshikazu Tanaka, Itsuto Hamano, Ayumu Kusaka, Hiromich Iwamura, Naoki Fujita, Hayato Yamamoto, Yuki Tobisawa, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Chikara Ohyama

Published in: International Journal of Clinical Oncology | Issue 1/2018

Abstract

Background

Clinical benefits of presurgical axitinib therapy for renal cell carcinoma (RCC) extending into the inferior vena cava (IVC) remain unclear. We aimed to investigate surgical benefits and pathological antitumor effects of presurgical axitinib therapy for RCC with IVC thrombus.

Methods

Of 56 consecutive RCC patients with IVC thrombus between January 1994 and December 2016, 41 patients who underwent radical nephrectomy (RN) were categorized as upfront RN (Upfront group) or presurgical axitinib followed by RN (Presurgical group). We retrospectively evaluated safety, radiologic tumor responses, and Ki-67 proliferation index before and after axitinib administration in the Presurgical group. Surgical outcomes, postoperative complications, and fibrosis within the IVC thrombus were compared between the Upfront and Presurgical groups.

Results

The number of patients in the Upfront and Presurgical groups was 31 and 10, respectively. Major presurgical axitinib-related adverse events were grade 2 or 3 hypertension (50%). The median radiological tumor response in the renal tumor, IVC thrombus length, and IVC thrombus volume were −19%, −21 mm, and −54%, respectively. The fibrosis within the IVC thrombus was significantly higher in the Presurgical group (10%) than in the Upfront group (3.4%). The Ki-67 proliferation index was significantly decreased in RN specimens (7.3%) versus needle biopsy specimens (23%) in the Presurgical group. Blood loss and operative duration were significantly lower and shorter, respectively, in the Presurgical group than in the Upfront group.

Conclusions

Presurgical axitinib therapy enhanced tumor reduction accompanied by fibrosis and may contribute to surgical risk reduction for selected patients.

Karam JA, Devine CE, Urbauer DL et al (2014) Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol 66(5):874–880. doi:10.1016/j.eururo.2014.01.035 CrossRefPubMedPubMedCentral

Thomas AA, Rini BI, Lane BR et al (2009) Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 181(2):518–523. doi:10.1016/j.juro.2008.10.001 (discussion 523) CrossRefPubMed

Cowey CL, Amin C, Pruthi RS et al (2010) Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 28(9):1502–1507. doi:10.1200/jco.2009.24.7759 CrossRefPubMedPubMedCentral

Rini BI, Garcia J, Elson P et al (2012) The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. J Urol 187(5):1548–1554. doi:10.1016/j.juro.2011.12.075 CrossRefPubMed

Kondo T, Hashimoto Y, Kobayashi H et al (2010) Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects. Jpn J Clin Oncol 40(12):1173–1179. doi:10.1093/jjco/hyq150 CrossRefPubMed

Cost NG, Delacroix SE Jr, Sleeper JP et al (2011) The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol 59(6):912–918. doi:10.1016/j.eururo.2011.02.032 CrossRefPubMed

Sassa N, Kato M, Funahashi Y et al (2014) Efficacy of pre-surgical axitinib for shrinkage of inferior vena cava thrombus in a patient with advanced renal cell carcinoma. Jpn J Clin Oncol 44(4):370–373. doi:10.1093/jjco/hyu014 CrossRefPubMed

Yuki H, Kamai T, Kubota K et al (2014) Axitinib for preoperative downstaging of renal cell carcinoma with sarcomatoid differentiation and direct invasion of the duodenum and inferior vena cava: a case report. Onco Targets Ther 7:289–295. doi:10.2147/ott.s58089 PubMedPubMedCentral

Komatsubara M, Yamazaki M, Fujisaki A et al (2016) Tumor thrombus of renal cell carcinoma extending into the inferior vena cava, ovarian vein, and ureter treated with neoadjuvant axitinib. Urology 95:e3–e4. doi:10.1016/j.urology.2016.05.057 CrossRefPubMed

10.

Schrader AJ, Steffens S, Schnoeller TJ et al (2012) Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy? Int J Urol 19(10):903–907. doi:10.1111/j.1442-2042.2012.03065.x CrossRefPubMed

11.

Bigot P, Fardoun T, Bernhard JC et al (2014) Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful? World J Urol 32(1):109–114. doi:10.1007/s00345-013-1088-1 CrossRefPubMed

12.

Ujike T, Uemura M, Kawashima A et al (2016) Clinical and histopathological effects of presurgical treatment with sunitinib for renal cell carcinoma with inferior vena cava tumor thrombus at a single institution. Anticancer Drugs 27(10):1038–1043. doi:10.1097/cad.0000000000000422 CrossRefPubMedPubMedCentral

13.

Ljungberg B, Bensalah K, Bex A et al (2016) Guidelines on renal cell carcinoma. http://uroweb.org/wp-content/uploads/10-Renal-Cell-Carcinoma_LR1.pdf. Accessed 20 Mar 2017

14.

Charlson M, Szatrowski TP, Peterson J et al (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(11):1245–1251CrossRefPubMed

15.

Hatakeyama S, Yoneyama T, Hamano I et al (2013) Prognostic benefit of surgical management in renal cell carcinoma patients with thrombus extending to the renal vein and inferior vena cava: 17-year experience at a single center. BMC Urol 13:47. doi:10.1186/1471-2490-13-47 CrossRefPubMedPubMedCentral

16.

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216. doi:10.1093/jnci/92.3.205 CrossRefPubMed

17.

Koie T, Ohyama C, Okamoto A et al (2013) Presurgical therapy with axitinib for advanced renal cell carcinoma: a case report. BMC Res Notes 6:484. doi:10.1186/1756-0500-6-484 CrossRefPubMedPubMedCentral

18.

Rini BI, Plimack ER, Takagi T et al (2015) A phase II study of pazopanib in patients with localized renal cell carcinoma to optimize preservation of renal parenchyma. J Urol 194(2):297–303. doi:10.1016/j.juro.2015.03.096 CrossRefPubMed

19.

Hutson TE, Lesovoy V, Al-Shukri S et al (2013) Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 14(13):1287–1294. doi:10.1016/s1470-2045(13)70465-0 CrossRefPubMed

20.

Hosogoe S, Hatakeyama S, Kusaka A et al (2017) Contrast media enhancement reduction predicts tumor response to presurgical molecular-targeting therapy in patients with advanced renal cell carcinoma. Oncotarget. doi:10.18632/oncotarget.17930

21.

Chery LJ, Karam JA, Wood CG (2016) Cytoreductive nephrectomy for metastatic renal cell carcinoma. Clin Adv Hematol Oncol 14(9):696–703PubMed

Title: Presurgical axitinib therapy increases fibrotic reactions within tumor thrombus in renal cell carcinoma with thrombus extending to the inferior vena cava
Authors: Yoshimi Tanaka
Shingo Hatakeyama
Shogo Hosogoe
Toshikazu Tanaka
Itsuto Hamano
Ayumu Kusaka
Hiromich Iwamura
Naoki Fujita
Hayato Yamamoto
Yuki Tobisawa
Tohru Yoneyama
Takahiro Yoneyama
Yasuhiro Hashimoto
Takuya Koie
Chikara Ohyama
Publication date: 01-02-2018
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 1/2018
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-017-1169-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Hereditary breast cancer: molecular biology and management update

Significance of multiple preoperative laboratory abnormalities as prognostic indicators in patients with urothelial carcinoma of the upper urinary tract following radical nephroureterectomy

Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma

Impact of major different variants of papillary thyroid microcarcinoma on the clinicopathological characteristics: the study of 1041 cases

Aspirin use and head and neck cancer survival: an observational study of 11,623 person-years follow-up

Concordance of clinical diagnosis of T classification among physicians for locally advanced unresectable thoracic esophageal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer